Congcong Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Congcong Hou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chunling Ma
College of Forensic Medicine, Hebei Medical University, Shijiazhuang 050017, China
1 shared publication Chunting Guan
College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang, PR China
1 shared publication- Dan Zhou
College of Forensic Medicine, Hebei Medical University, Shijiazhuang 050017, China
1 shared publication Jiameng Dong
College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang, PR China
1 shared publication- Jian-Hong Shi
Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University, Baoding, China (J.S., Yiyi Zhang, C.W.).
1 shared publication Jun Sun
College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang, PR China
1 shared publication
Latest Publications
- Open Access
- 31 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5000
Subthreshold Thermal Stress Aggravates Methamphetamine-Induced Cardiomyocyte Pyroptosis via the Mitochondrial ROS/BAX/mtDNA/NLRP3 Pathway
Methamphetamine (METH)-induced cardiomyocyte injury is the leading cause of mortality beyond acute intoxication. METH abuse often occurs in crowded, poorly ventilated environments, and even moderately high ambient temperatures exacerbate METH-related cardiovascular emergencies. However, the underlying mechanisms by which environmental factors drive the progression of cardiac diseases remain poorly understood. This study modeled the real-world scenario in vivo by exposing mice to METH under normothermic condition (NC, 22 °C) or subthreshold thermal stress (STS, 28 °C, a mild thermal challenge for mice) conditions, and in vitro by using H9c2 cardiomyocytes exposed to METH at 37 °C or 39 °C. STS significantly potentiated METH-induced cardiac dysfunction, mitochondrial ultrastructural damage, and oxidative stress (p < 0.05). Mechanistically, the co-exposure impaired mitochondrial respiratory chain complex I and led to excessive mitochondrial ROS (mtROS) production, activating the pro-apoptotic protein BAX, causing mitochondrial outer membrane (MOM) permeabilization and the cytosolic release of mitochondrial DNA (mtDNA). Cytosolic mtDNA-mediated NLRP3 inflammasome activation subsequently executed cardiomyocyte pyroptosis via caspase-1/Gasdermin D (p < 0.05). Crucially, the mitochondria-targeted antioxidant mitoquinone (MitoQ) substantially attenuated the aggravated cardiotoxicity by scavenging the initial mtROS (p < 0.05), thereby preventing the activation of the downstream BAX/mtDNA/NLRP3 axis. These findings provide evidence for a defined signaling basis for this drug-environment interaction and highlight mitochondrial redox modulation as a potential therapeutic strategy for psychostimulant-associated cardiovascular injury.
- 31 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5000
Open AccessSubthreshold Thermal Stress Aggravates Methamphetamine-Induced Cardiomyocyte Pyroptosis via the Mitochondrial ROS/BAX/mtDNA/NLRP3 Pathway
Methamphetamine (METH)-induced cardiomyocyte injury is the leading cause of mortality beyond acute intoxication. METH abuse often occurs in crowded, poorly ventilated environments, and even moderately high ambient temperatures exacerbate METH-related cardiovascular emergencies. However, the underlying mechanisms by which environmental factors drive the progression of cardiac diseases remain poorly understood. This study modeled the real-world scenario in vivo by exposing mice to METH under normothermic condition (NC, 22 °C) or subthreshold thermal stress (STS, 28 °C, a mild thermal challenge for mice) conditions, and in vitro by using H9c2 cardiomyocytes exposed to METH at 37 °C or 39 °C. STS significantly potentiated METH-induced cardiac dysfunction, mitochondrial ultrastructural damage, and oxidative stress (p < 0.05). Mechanistically, the co-exposure impaired mitochondrial respiratory chain complex I and led to excessive mitochondrial ROS (mtROS) production, activating the pro-apoptotic protein BAX, causing mitochondrial outer membrane (MOM) permeabilization and the cytosolic release of mitochondrial DNA (mtDNA). Cytosolic mtDNA-mediated NLRP3 inflammasome activation subsequently executed cardiomyocyte pyroptosis via caspase-1/Gasdermin D (p < 0.05). Crucially, the mitochondria-targeted antioxidant mitoquinone (MitoQ) substantially attenuated the aggravated cardiotoxicity by scavenging the initial mtROS (p < 0.05), thereby preventing the activation of the downstream BAX/mtDNA/NLRP3 axis. These findings provide evidence for a defined signaling basis for this drug-environment interaction and highlight mitochondrial redox modulation as a potential therapeutic strategy for psychostimulant-associated cardiovascular injury.
- 7 August 2025
- Published by Springer Nature in Biological Trace Element Research
- Vol. 204 (3) , 1678-1692
Vanadyl Acetylacetonate and Berberine Synergistically Ameliorate Diabetes-induced Vascular Dysfunction and Reduce Endothelial Toxicity through ERK and Akt Regulation
Vanadyl acetylacetonate (VO) and berberine (BBR) have both demonstrated anti-diabetic effects. Previous studies in type 1 diabetic rats suggest that their co-administration of VO and BBR is safer and more effective than either compound alone. However, the precise vascular effects and underlying molecular mechanisms remain unclear. Diabetic rats received VO, BBR, or both. Blood glucose and body weight were monitored. Alizarin Red staining detected vascular calcification. Vascular morphology, intercellular junctions (E-Cadherin/β-catenin staining), cytoskeleton (Phalloidin), and permeability (FITC-BSA) were assessed. Cell viability was evaluated via MTT assay, apoptosis kit, and flow cytometry. Western blotting analyzed Bax, Bcl-2, and related pathway proteins. NOS activity including tNOS and iNOS were measured. GO and KEGG pathway enrichment identified potential mechanisms. Co-administration of VO and BBR reduced blood glucose without affecting weight. It attenuated vascular calcification, preserved intercellular junctions, and improved endothelial barrier function. BBR reversed VO-induced E-Cadherin/β-catenin disruption, cytoskeletal damage, and permeability increase. Cell apoptosis reduced with BBR, associated with downregulation of Bax, upregulation of Bcl-2, and normalized tNOS and iNOS activity. Mechanistically, ERK and PI3K-Akt pathways were implicated. BBR suppressed VO-induced overactivation of p-ERK and p-Akt. VO and BBR synergistically improve glucose control and provide enhanced vascular protection more effectively than either compound alone in diabetic rats. Furthermore, BBR prevents the over-activation of ERK and Akt induced by VO, thereby reducing iNOS and tNOS production, subsequent apoptosis, intercellular junction damage, and increased permeability in HUVECs. These preliminary findings lay the groundwork for future research aimed at developing novel therapeutic strategies and safer anti-diabetic treatments with improved efficacy and reduced toxicity.
- 7 August 2025
- Published by Springer Nature in Biological Trace Element Research
- Vol. 204 (3) , 1678-1692
Vanadyl Acetylacetonate and Berberine Synergistically Ameliorate Diabetes-induced Vascular Dysfunction and Reduce Endothelial Toxicity through ERK and Akt Regulation
Vanadyl acetylacetonate (VO) and berberine (BBR) have both demonstrated anti-diabetic effects. Previous studies in type 1 diabetic rats suggest that their co-administration of VO and BBR is safer and more effective than either compound alone. However, the precise vascular effects and underlying molecular mechanisms remain unclear. Diabetic rats received VO, BBR, or both. Blood glucose and body weight were monitored. Alizarin Red staining detected vascular calcification. Vascular morphology, intercellular junctions (E-Cadherin/β-catenin staining), cytoskeleton (Phalloidin), and permeability (FITC-BSA) were assessed. Cell viability was evaluated via MTT assay, apoptosis kit, and flow cytometry. Western blotting analyzed Bax, Bcl-2, and related pathway proteins. NOS activity including tNOS and iNOS were measured. GO and KEGG pathway enrichment identified potential mechanisms. Co-administration of VO and BBR reduced blood glucose without affecting weight. It attenuated vascular calcification, preserved intercellular junctions, and improved endothelial barrier function. BBR reversed VO-induced E-Cadherin/β-catenin disruption, cytoskeletal damage, and permeability increase. Cell apoptosis reduced with BBR, associated with downregulation of Bax, upregulation of Bcl-2, and normalized tNOS and iNOS activity. Mechanistically, ERK and PI3K-Akt pathways were implicated. BBR suppressed VO-induced overactivation of p-ERK and p-Akt. VO and BBR synergistically improve glucose control and provide enhanced vascular protection more effectively than either compound alone in diabetic rats. Furthermore, BBR prevents the over-activation of ERK and Akt induced by VO, thereby reducing iNOS and tNOS production, subsequent apoptosis, intercellular junction damage, and increased permeability in HUVECs. These preliminary findings lay the groundwork for future research aimed at developing novel therapeutic strategies and safer anti-diabetic treatments with improved efficacy and reduced toxicity.